Membrane-targeting AM-0016 kills mycobacterial persisters and shows low propensity for resistance development

Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses

(2015) Anne Lenaerts et al.   IMMUNOLOGICAL REVIEWS

The new tuberculosis drug Perchlozone® shows cross-resistance with thiacetazone

(2015) Pooja Gopal et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents

(2014) Suresh B. Lakshminarayana et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Amino Acid Modified Xanthone Derivatives: Novel, Highly Promising Membrane-Active Antimicrobials for Multidrug-Resistant Gram-Positive Bacterial Infections

(2014) Jun-Jie Koh et al.   JOURNAL OF MEDICINAL CHEMISTRY

Reduced Drug Uptake in Phenotypically Resistant Nutrient-Starved Nonreplicating Mycobacterium tuberculosis

(2013) Jansy Sarathy et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Design and Synthesis of Amphiphilic Xanthone-Based, Membrane-Targeting Antimicrobials with Improved Membrane Selectivity

(2013) Hanxun Zou et al.   JOURNAL OF MEDICINAL CHEMISTRY

Rapid bactericidal action of alpha-mangostin against MRSA as an outcome of membrane targeting

(2012) Jun-Jie Koh et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES

Characterization and Transcriptome Analysis of Mycobacterium tuberculosis Persisters

(2011) I. Keren et al.   mBio

Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections

(2010) Julian G. Hurdle et al.   NATURE REVIEWS MICROBIOLOGY

The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis

(2008) S. P. S. Rao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA